Clinical Trial Update: Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease [Phase 4]

View source ↗

Summary

Phase 4 trial update for Acthar in patients with systemic lupus erythematosus (SLE) who have persistently active disease; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Acthar (repository corticotropin injection)

Snippet

Sponsor: Mallinckrodt | Conditions: Systemic Lupus Erythematosus (SLE) | Phase 4 | Status: COMPLETED | Results posted: 2020-02-27